The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
Glucocorticoids in the treatment of rheumatic diseases: An update on the mechanisms of action
Abstract
Six years after we published our first article on the mechanisms of action of glucocorticoids (GCs) (1), there is already a need for an update. GCs are superior to many drugs in terms of the number of patients treated, the variety of potential uses, and the experience with treatment in humans. They still represent the most important and most frequently used class of antiinflammatory drugs, and their therapeutic use has risen continuously in recent years (2). About 10 million new prescriptions for oral GCs are written each year in the US alone (2). They are the silent companions of rheumatologists, and it is impossible to imagine therapy— especially oral therapy, but intravenous and intraarticular as well—without them. From community survey data, the frequency of oral GC use has been estimated to be 0.5% of the general population and 1.75% of women over the age of 55 years (3,4). Between 56% and 68% of patients with rheumatoid arthritis are treated more or less continuously with GCs (5–8). GCs are relatively inexpensive drugs, but it is the sheer volume used that is significant overall; the total market size is believed to be about 10 billion US dollars per year (2). Our understanding of the actions of GCs has also greatly increased in the last few years. In this review, we report on recent insights relating to 1) signaling, transcription processes, and gene expression as induced, inhibited, and/or modified by the interaction of GCs with their cytosolic receptors, 2) relationships between dosages and plasma levels, 3) membrane-bound GC receptors (GCRs), and 4) new (glucocorticoid) drugs on the horizon. These data support the modular concept we proposed in 1998 (1), and so this update follows the same structure.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mechanisms involved in the side effects of glucocorticoids
SCHACKE, H. (2002) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(02)00297-8 · Cited by 1,847
Etanercept Therapy in Rheumatoid Arthritis: A Randomized, Controlled Trial
Moreland, L. W., Schiff, M. H., Baumgartner, S. W., Tindall, E. A., Fleischmann, R. M., Bulpitt, K. J., Weaver, A. L., Keystone, E. C., Furst, D. E., Mease, P. J., et al. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-6-199903160-00004 · Cited by 1,379
Nongenomic actions of steroid hormones
Lösel, R., & Wehling, M. (2003) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1009 · Cited by 980
Self-citationMolecular Determinants of Glucocorticoid Receptor Function and Tissue Sensitivity to Glucocorticoids
BAMBERGER, C. M., SCHULTE, H. M., & CHROUSOS, G. P. (1996) · Endocrine Reviews · doi:10.1210/edrv-17-3-245 · Cited by 889
BRI1 is a critical component of a plasma-membrane receptor for plant steroids
Wang, Z.-Y., Seto, H., Fujioka, S., Yoshida, S., & Chory, J. (2001) · Nature · doi:10.1038/35066597 · Cited by 846
Hafezi-Moghadam, A., Simoncini, T., Yang, Z., Limbourg, F. P., Plumier, J.-C., Rebsamen, M. C., Hsieh, C.-M., Chui, D.-S., Thomas, K. L., Prorock, A. J., et al. (2002) · Nature Medicine · doi:10.1038/nm0502-473 · Cited by 594
Buttgereit, F., Da Silva, J. A. P., Boers, M., Burmester, G.-R., Cutolo, M., Jacobs, J., Kirwan, J., Köhler, L., van Riel, P., Vischer, T., et al. (2002) · Annals of the Rheumatic Diseases · doi:10.1136/ard.61.8.718 · Cited by 544
Self-citationA corticosteroid receptor in neuronal membranes
Orchinik, M., Murray, T. F., & Moore, F. L. (1991) · Science · doi:10.1126/science.2063198 · Cited by 523
Schäcke, H., Schottelius, A., Döcke, W.-D., Strehlke, P., Jaroch, S., Schmees, N., Rehwinkel, H., Hennekes, H., & Asadullah, K. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0300372101 · Cited by 466
Li, L., Haynes, M. P., & Bender, J. R. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0831079100 · Cited by 465
Pratt, W. B. (1998) · Experimental Biology and Medicine · doi:10.3181/00379727-217-44252 · Cited by 447
A New First Step in Activation of Steroid Receptors
Davies, T. H., Ning, Y.-M., & Sánchez, E. R. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.c100531200 · Cited by 427
Fleischmann, R. M., Schechtman, J., Bennett, R., Handel, M. L., Burmester, G., Tesser, J., Modafferi, D., Poulakos, J., & Sun, G. (2003) · Arthritis & Rheumatism · doi:10.1002/art.10870 · Cited by 392
Self-citationWalsh, L. J., Wong, C. A., Pringle, M., & Tattersfield, A. E. (1996) · BMJ · doi:10.1136/bmj.313.7053.344 · Cited by 383
Rapid Actions of Steroid Receptors in Cellular Signaling Pathways
Cato, A. C. B., Nestl, A., & Mink, S. (2002) · Science's STKE · doi:10.1126/stke.2002.138.re9 · Cited by 369
Izenstein, B. Z. (1996) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1996.03530350062036 · Cited by 359
De Bosscher, K., Vanden Berghe, W., Vermeulen, L., Plaisance, S., Boone, E., & Haegeman, G. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.8.3919 · Cited by 335
Croxtall, J. D., Choudhury, Q., & Flower, R. J. (2000) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0703272 · Cited by 332
Rapid glucocorticoid effects on immune cells
Buttgereit, F., & Scheffold, A. (2002) · Steroids · doi:10.1016/s0039-128x(01)00171-4 · Cited by 318
Self-citationMetselaar, J. M., Wauben, M. H. M., Wagenaar‐Hilbers, J. P. A., Boerman, O. C., & Storm, G. (2003) · Arthritis & Rheumatism · doi:10.1002/art.11140 · Cited by 302
Ikappa Balpha -independent downregulation of NF-kappa B activity by glucocorticoid receptor
Heck, S. (1997) · The EMBO Journal · doi:10.1093/emboj/16.15.4698 · Cited by 295
Weinblatt, M. E., Kremer, J. M., Coblyn, J. S., Maier, A. L., Helfgott, S. M., Morrell, M., Byrne, V. M., Kaymakcian, M. V., & Strand, V. (1999) · Arthritis & Rheumatism · doi:10.1002/1529-0131(199907)42:7<1322::aid-anr4>3.0.co;2-p · Cited by 286
Stavreva, D. A., Müller, W. G., Hager, G. L., Smith, C. L., & McNally, J. G. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.7.2682-2697.2004 · Cited by 264
Guillevin, L., Cohen, P., Mahr, A., Arène, J., Mouthon, L., Puéchal, X., Pertuiset, E., Gilson, B., Hamidou, M., Lanoux, P., et al. (2003) · Arthritis Care & Research · doi:10.1002/art.10922 · Cited by 251
Vacca, A., Felli, M. P., Farina, A. R., Martinotti, S., Maroder, M., Screpanti, I., Meco, D., Petrangeli, E., Frati, L., & Gulino, A. (1992) · The Journal of experimental medicine · doi:10.1084/jem.175.3.637 · Cited by 241
Bartholome, B., Spies, C. M., Gaber, T., Schuchmann, S., Berki, T., Kunkel, D., Bienert, M., Radbruch, A., Burmester, G., Lauster, R., et al. (2004) · The FASEB Journal · doi:10.1096/fj.03-0328com · Cited by 229
Self-citationButtgereit, F., Wehling, M., & Burmester, G.-R. (1998) · Arthritis & Rheumatism · doi:10.1002/1529-0131(199805)41:5<761::aid-art2>3.0.co;2-m · Cited by 226
Self-citationSchmidt, J., Metselaar, J. M., Wauben, M. H. M., Toyka, K. V., Storm, G., & Gold, R. (2003) · Brain · doi:10.1093/brain/awg176 · Cited by 204
Corticosteroid-insensitive asthma: molecular mechanisms
Adcock, I., & Lane, S. (2003) · Journal of Endocrinology · doi:10.1677/joe.0.1780347 · Cited by 179
Molecular Origins for the Dominant Negative Function of Human Glucocorticoid Receptor Beta
Yudt, M. R., Jewell, C. M., Bienstock, R. J., & Cidlowski, J. A. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.12.4319-4330.2003 · Cited by 175
Mannheim Classification of Nongenomically Initiated (Rapid) Steroid Action(s)
Falkenstein, E., Norman, A. W., & Wehling, M. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.85.5.2072 · Cited by 162
Self-citationGametchu, B., Watson, C. S., & Wu, S. (1993) · The FASEB Journal · doi:10.1096/fasebj.7.13.8405814 · Cited by 117
Youssef, P. P., Haynes, D. R., Triantafillou, S., Parker, A., Gamble, J. R., Roberts-Thomson, P. J., Ahern, M. J., & Smith, M. D. (1997) · Arthritis & Rheumatism · doi:10.1002/art.1780400807 · Cited by 112
Intravenous pulses of methylprednisolone for systemic lupus erythematosus
Badsha, H., & Edwards, C. J. (2003) · Seminars in Arthritis and Rheumatism · doi:10.1053/sarh.2002.50003 · Cited by 110
Paul‐Clark, M. J., Mancini, L., Soldato, P. D., Flower, R. J., & Perretti, M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.022641099 · Cited by 79
Fiorucci, S., Antonelli, E., Distrutti, E., Soldato, P. D., Flower, R. J., Clark, M. J. P., Morelli, A., Perretti, M., & Ignarro, L. J. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.232583599 · Cited by 76
Methylprednisolone versus prednisolone pharmacokinetics in relation to dose in adults
Szefler, S. J., Ebling, W. F., Georgitis, J. W., & Jusko, W. J. (1986) · European Journal of Clinical Pharmacology · doi:10.1007/bf00541537 · Cited by 74
Methylprednisolone pharmacokinetics after intravenous and oral administration.
Al‐Habet, S., & Rogers, H. (1989) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1989.tb05366.x · Cited by 73
Lazaroids: efficacy and mechanism of action of the 21-aminosteroids in neuroprotection
Kavanagh, R. J., & Kam, P. C. A. (2001) · British Journal of Anaesthesia · doi:10.1093/bja/86.1.110 · Cited by 73
The plasma membrane estrogen receptor: nuclear or unclear?
Nadal, Á., Ropero, A. B., Fuentes, E., & Soria, B. (2001) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(00)01846-0 · Cited by 71
Mori, A., Kaminuma, O., Suko, M., Inoue, S., Ohmura, T., Hoshino, A., Asakura, Y., Miyazawa, K., Yokota, T., Okumura, Y., et al. (1997) · Blood · doi:10.1182/blood.v89.8.2891 · Cited by 67
Paul‐Clark, M. J., Roviezzo, F., Flower, R. J., Cirino, G., Soldato, P. D., Adcock, I. M., & Perretti, M. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.6.3245 · Cited by 64
Wikström, A. C. (2003) · Journal of Endocrinology · doi:10.1677/joe.0.1780331 · Cited by 61
Chen, F., Watson, C. S., & Gametchu, B. (1999) · Journal of Cellular Biochemistry · doi:10.1002/(sici)1097-4644(19990901)74:3<430::aid-jcb11>3.0.co;2-5 · Cited by 61
Glucocorticoids Inhibit Calcium- and Calcineurin-Dependent Activation of the Human IL-4 Promoter
Chen, R., Burke, T. F., Cumberland, J. E., Brummet, M. E., Beck, L. A., Casolaro, V., & Georas, S. N. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.2.825 · Cited by 59
Kinetics of methylprednisolone and its hemisuccinate ester
Derendorf, H., Möllmann, H., Rohdewald, P. J., et al. (1985) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1985.79 · Cited by 59
Zink, A., Listing, J., Niewerth, M., & Zeidler, H. (2001) · Annals of the Rheumatic Diseases · doi:10.1136/ard.60.3.207 · Cited by 57
Diba, F., Watson, C. S., & Gametchu, B. (2001) · Journal of Cellular Biochemistry · doi:10.1002/1097-4644(20010401)81:1<149::aid-jcb1031>3.0.co;2-w · Cited by 54
Murphy, P. J. M., Morishima, Y., Chen, H., Galigniana, M. D., Mansfield, J. F., Simons, S. S., & Pratt, W. B. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m304469200 · Cited by 53
Sanden, S., Tripmacher, R., Weltrich, R., Rohde, W., Hiepe, F., Gr, B., & Buttgereit, F. (2000) · PubMed · Cited by 51
Self-citationLin, C. W., Nakane, M., Stashko, M., Falls, D. H., Kuk, J. E., Miller, L. N., Huang, R., Tyree, C. M., Miner, J. N., Rosen, J., et al. (2002) · Molecular Pharmacology · doi:10.1124/mol.62.2.297 · Cited by 49
Jacobs, J. W. G., Geenen, R., Evers, A. W. M., van Jaarsveld, C. H. M., Kraaimaat, F., & Bijlsma, J. W. J. (2001) · Annals of the Rheumatic Diseases · doi:10.1136/ard.60.1.61 · Cited by 47
Kanelakis, K. C., Shewach, D. S., & Pratt, W. B. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m204164200 · Cited by 39
Hayball, P. J., Cosh, D. G., Ahern, M. J., et al. (1992) · European Journal of Clinical Pharmacology · doi:10.1007/bf00314925 · Cited by 38
Missed opportunities in physician management of glucocorticoid‐induced osteoporosis?
Ramsey‐Goldman, R. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10619 · Cited by 29
Folding and stability of the ligand‐binding domain of the glucocorticoid receptor
McLaughlin, S. H., & Jackson, S. (2002) · Protein Science · doi:10.1110/ps.5000102 · Cited by 26
Perretti, M., Paul‐Clark, M. J., Mancini, L., & Flower, R. J. (2003) · Digestive and Liver Disease · doi:10.1016/s1590-8658(03)00051-3 · Cited by 25
Enhanced anti‐inflammatory potency of a nitric oxide‐releasing prednisolone derivative in the rat
Turesin, F., Soldato, P. D., & Wallace, J. L. (2003) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705324 · Cited by 24
Glucocorticoid biology — a molecular maze and clinical challenge
Goulding, N. J., & Flower, R. J. (2001) · Birkhäuser Basel eBooks · doi:10.1007/978-3-0348-8348-1_1 · Cited by 11
Dissemond, J., Schneider, L. A., Wlaschek, M., Brauns, T. C., Goos, M., & Scharffetter‐Kochanek, K. (2003) · Archives of Dermatological Research · doi:10.1007/s00403-003-0432-5 · Cited by 6
Cited by
Genomic and nongenomic effects of glucocorticoids
Stahn, C., & Buttgereit, F. (2008) · Nature Clinical Practice Rheumatology · doi:10.1038/ncprheum0898 · Cited by 594
Dose-related patterns of glucocorticoid-induced side effects
Huscher, D., Thiele, K., Gromnica-Ihle, E., Hein, G., Demary, W., Dreher, R., Zink, A., & Buttgereit, F. (2009) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.092163 · Cited by 604
Self-citationWolfe, F., Caplan, L., & Michaud, K. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21568 · Cited by 480
Strategies toward rheumatoid arthritis therapy; the old and the new
Abbasi, M., Mousavi, M. J., Jamalzehi, S., Alimohammadi, R., Bezvan, M. H., Mohammadi, H., & Aslani, S. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.27860 · Cited by 443
Molecular mechanisms of glucocorticoid action and selective glucocorticoid receptor agonists
Stahn, C., Löwenberg, M., Hommes, D. W., & Buttgereit, F. (2007) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2007.05.019 · Cited by 419
Self-citation
Metadata
- Authors
- Buttgereit, F., Straub, R. H., Wehling, M., & Burmester, G.
- Venue
- Arthritis & Rheumatism
- Publisher
- Wiley
- Published
- 2004-11
- Volume
- 50
- Issue
- 11
- Pages
- 3408-3417
- ISSN
- 0004-3591 (ISSN-L)
- 1529-0131
- OpenAlex
- W2063467177
- Cited by
- 367
- References
- 60
- FWCI
- 9.38
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.